Reverse Settlements Are Acceptable Under Certain Conditions, DoJ Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand company payments to generic firms to settle infringement suits may not violate antitrust laws if they permit some competition, Department of Justice concludes.
You may also be interested in...
Patent Settlement Bill Advances - And Firms Fight Back With Examples Of Early Generic Launches That Would Be Prohibited
Four years ago, Teva inked a patent litigation settlement with Wyeth that enabled it to launch generic Effexor XR seven years before the patent on the drug expired
Patent Settlement Bill Advances - And Firms Fight Back With Examples Of Early Generic Launches That Would Be Prohibited
Four years ago, Teva inked a patent litigation settlement with Wyeth that enabled it to launch generic Effexor XR seven years before the patent on the drug expired
Patent Settlements: 2nd Circuit Okays Bayer's Cipro Deal But Doesn't Want To
While the U.S. Court of Appeals for the Second Circuit found that a reverse settlement agreement involving Bayer's antibiotic Cipro did not violate antitrust laws, it invited the plaintiffs to seek a reexamination of the case by the full court